Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “bupropion”

16 pharma patents match "bupropion" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 16
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 16 pharmaceutical patents matching "bupropion" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

16 results for “bupropion” · 30,257 patents in full index Clear search

  1. US 12357697

    Pharmaceutical compositions comprising bupropion and cysteine

    AXSOME THERAPEUTICS, INC. · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  2. US 12156914

    Pharmaceutical compositions comprising bupropion and cysteine

    AXSOME THERAPEUTICS, INC. · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  3. US 12102606

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  4. US 11786488

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  5. US 11660274

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted May 30, 2023 · Expires May 25, 2043

    granted
  6. US 11433035

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  7. US 11344514

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted May 31, 2022 · Expires May 26, 2042

    granted
  8. US 11344513

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted May 31, 2022 · Expires May 26, 2042

    granted
  9. US 11331285

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted May 17, 2022 · Expires May 12, 2042

    granted
  10. US 11291639

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  11. US 11179351

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted
  12. US 11179352

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted
  13. US 11129826

    Bupropion as a modulator of drug activity

    AXSOME THERAPEUTICS, INC. · Granted Sep 28, 2021 · Expires Sep 23, 2041

    granted
  14. US 11123344

    Bupropion as a modulator of drug activity

    AXSOME THERAPEUTICS, INC. · Granted Sep 21, 2021 · Expires Sep 16, 2041

    granted
  15. US 10695304

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted Jun 30, 2020 · Expires Jun 25, 2040

    granted
  16. US 6306436

    Stabilized, acid-free formulation for sustained release of bupropion hydrochloride

    Teva Pharmaceuticals USA, Inc. · Granted Oct 23, 2001 · Expires Oct 18, 2021

    expired